Daiichi Sankyo Announces New Enhertu Trial Data in Breast and Lung Cancer at ESMO 2026

• Daiichi Sankyo will present more than 30 oncology abstracts, including four late-breaking presentations, at ESMO 2026 on October 23-26.
• Updates from six Phase 3 trials support Enhertu and Datroway's potential to advance treatment standards in breast and lung cancer.
• Two ovarian cancer trials show emerging potential for raludotatug deruxtecan; forthcoming presentations cover its use alone or with bevacizumab.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610220700BIZWIRE_USPR_____20261021_BW091765) on October 22, 2026, and is solely responsible for the information contained therein.